68Ga/177Lu标记的FAP靶向肽用于肿瘤放射性药物成像与治疗的临床前评价
本研究设计新型FAP靶向肽FAP-HXN,在人胚胎肾(HEK)-293-FAP细胞及荷瘤小鼠中评估其选择性、亲和力及诊疗潜力,并与FAP-2286对比。结果显示[68Ga]Ga-FAP-HXN在FAP阳性肿瘤中持续摄取,[177Lu]Lu-FAP-HXN在耐受剂量下显示显著抗肿瘤活性、更长肿瘤滞留及更好肿瘤生长抑制。
要点
- FAP-HXN对人源和小鼠源FAP均具有高结合能力。
- [68Ga]Ga-FAP-HXN在FAP阳性肿瘤中较[68Ga]Ga-FAP-2286显示持续肿瘤摄取。
- [177Lu]Lu-FAP-HXN在耐受剂量下显示显著抗肿瘤活性,肿瘤滞留更长、生长抑制优于[177Lu]Lu-FAP-2286。
核心结论
- 临床前研究显示放射性标记的FAP-HXN在HEK-293-FAP异种移植瘤中具有高肿瘤摄取、延长滞留和显著抗癌疗效。
- FAP-HXN作为针对FAP阳性肿瘤的新型诊疗放射性配体显示出有前景的潜力。
研究设计与样本
- 本研究合成FAP-HXN并表征其对FAP的选择性和特异性。
- 在FAP高表达的人胚胎肾(HEK)-293-FAP细胞中评估放射性标记FAP-HXN的细胞摄取。
- 在HEK-293-FAP荷瘤小鼠中评估68Ga和177Lu标记放射性配体的诊断和治疗潜力,并与FAP靶向肽FAP-2286比较。
主要发现
- FAP-HXN对人源和小鼠源FAP均具有高结合能力。
- 体内研究证实放射性标记FAP-HXN具有高亲和力和特异性。
- 小动物PET显像显示[68Ga]Ga-FAP-HXN给药后在FAP阳性肿瘤中较[68Ga]Ga-FAP-2286具有持续肿瘤摄取。
- 治疗实验中[177Lu]Lu-FAP-HXN在耐受剂量下对HEK-293-FAP异种移植瘤显示显著抗肿瘤活性,且较[177Lu]Lu-FAP-2286显示更长肿瘤滞留和更好肿瘤生长抑制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Fibroblast activation protein (FAP) has been considered a promising target for tumor imaging and therapy. This study designed a novel peptide, FAP-HXN, specifically targeting FAP and exhibiting significant potential as a radionuclide-labeled theranostic agent. Preclinical studies were conducted to evaluate the potency, selectivity, and efficacy of FAP-HXN. Methods: FAP-HXN was synthesized and characterized for selectivity and specificity toward FAP. Cellular uptake of the radiolabeled FAP-HXN in human embryonic kidney (HEK)-293-FAP cells with high expressions of FAP was evaluated. The diagnostic and therapeutic potential of 68Ga- and 177Lu-labeled radioligands was evaluated in HEK-293-FAP tumor-bearing mice compared with the FAP-targeting peptide FAP-2286. Results: FAP-HXN demonstrated high binding ability to human and mouse sources of FAP. Moreover, the in vivo studies confirmed the high affinity and specificity of radiolabeled FAP-HXN. Small-animal PET imaging demonstrated that [68Ga]Ga-FAP-HXN had continuous tumor uptake in FAP-positive tumors after administration compared with [68Ga]Ga-FAP-2286. In the therapeutic experiments, [177Lu]Lu-FAP-HXN showed significant antitumor activity in HEK-293-FAP xenografts at well-tolerated doses, which also exhibited longer tumor retention and better tumor growth inhibition compared with [177Lu]Lu-FAP-2286. Conclusion: The preclinical studies revealed that radiolabeled FAP-HXN had high tumor uptake, prolonged retention, and significant anticancer efficacy in HEK-293-FAP xenografts. FAP-HXN shows promising potential as a novel theranostic radioligand for FAP-positive tumors.
引用
- Wang R, Huang M, Wang W, et al. Preclinical Evaluation of 68Ga/177Lu-Labeled FAP-Targeted Peptide for Tumor Radiopharmaceutical Imaging and Therapy. J Nucl Med. 2025. PMID: 39848766. doi:10.2967/jnumed.124.268689
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。